New discoveries in Alzheimer's genetics
An international study involving approximately 2.8 million people, including Lifelines participants, has identified 48 previously unknown genetic risk regions associated with Alzheimer's disease. The research, published in Nature in 2026, provides new insights into the biological processes behind the disease and identifies potential targets for future drug development.
Background
Alzheimer's disease is the most common cause of dementia worldwide. Although genetics plays an important role in the development of the disease, many of the genetic factors involved remain unknown.
Researchers from the Alzheimer's Disease Working Group of the Psychiatric Genomics Consortium (PGC-ALZ) analysed genetic data from 30 cohorts, including Lifelines. The study combined data from people with and without Alzheimer's disease, as well as individuals who reported that a parent had Alzheimer's disease or dementia.
The researchers identified 127 genetic risk regions, including 48 that had not been identified before. Their findings also revealed genetic associations involving specific brain cells, particularly microglia (immune cells in the brain) and neurons. These findings provide further insights into the biological processes associated with Alzheimer's disease.
Impact for more healthy years
The findings contribute to a better understanding of the genetic mechanisms underlying Alzheimer's disease and highlight several potential targets for future drug development. The researchers also improved genetic risk prediction, providing new insights into the inherited risk of developing Alzheimer's disease.
Interested in using Lifelines data and biosamples for your research?